Irinotecan as a new agent for urachal cancer

Urologia Internationalis

Volumn 76, Issue 3, 2006, Pages 281-282

  Kume, Haruki ^a,b   Tomita, Kyoichi ^a   Takahashi, Sayuri ^b   Fukutani, Keiko ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b Asoka Hospital   (Japan)

Author keywords

Carcinoembryonic antigen; Irinotecan; Urachal cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; MUCIN;

ADULT; ANOREXIA; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SURGERY; CASE REPORT; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG METASTASIS; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; SERUM; URACHUS;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; HUMANS; MALE; MIDDLE AGED; URACHUS;

EID: 33645699804     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091635     Document Type: Article

References (5)

1. Tomita K, Tobisu KI, Kume H, Fujimoto H, Kakizoe T: Long survival with extended surgery for urachal carcinoma involving adjacent organs. J Urol 1998;159:1298.
2. Kimura M, Morishita H, Tanikawa T, Wakatsuki H: A case report of urachal carcinoma with peritonitis carcinomatosa which was well treated by M-FAP therapy. Urol Surg 1995;8: 821-823.
3. Logothetis CJ, Samuels ML, Ogden S: Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-c. Urology 1985;26:252-255.
4. Gill S, Goldberg RM: First-line treatment strategies to improve survival in patients with advanced colorectal cancer. Drugs 2004;64:27-44.
5. Kawakami S, Kageyama Y, Yonese J, Fukui I, Kitahara S, Arai G, Hyouchi N, Suzuki M, Masuda H, Hayashi T, Okuno T, Kihara K: Successful treatment of metastatic adenocarcinoma of the urachus: report of 2 cases with more than 10-year survival. Urology 2001;58:462.